There is little evidence to support the use of PET/CT imaging in the pre-operative staging of primary colorectal cancer, according to research published in the October edition of Health Technology Assessment.
Over the next decade, the population of cancer survivors over 65 years of age will increase by approximately 42 percent, according to a report published in the October issue of Cancer Epidemiology, Biomarkers & Prevention.
Infinitt North America, a developer of image and information management technologies for healthcare, has received FDA clearance for its fusion software, Xelis Fusion. The software is now available to the North American market.
PET imaging is showing a 7 percent average annual growth rate from 2008 to 2010, which is a decrease from the average annual rate of 10.4 percent from 2005 to 2008, according to IMV's research report, 2011 PET Market Summary Report.
A steady reduction in overall cancer death rates translates into the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society (ACS).
A class of engineered nanoparticles—Raman-silica-gold-nanoparticles—has been shown to be safe when administered by two alternative routes in mouse models, according to a study published April 20 in Science Translational Medicine. This marks the first step up the ladder of toxicology studies that, within a year and a half, could yield to human trials of these agents for detection of colorectal and possibly other cancers.
Avoiding contact laxatives is necessary to decrease intestinal artifacts in PET/CT image interpretation and a low-residue diet is not beneficial for colonic preparation, according to a study published in the April issue of Nuclear Medicine Communications.
Pretargeted immunoPET with Immunomedics' TF2 and gallium-68 (68Ga)-labeled peptide is a sensitive imaging method for colon cancer and is more specific than FDG PET, according to results presented at the annual meeting of the American Association for Cancer Research (AACR) this week in Orlando, Fla.
Overall cancer incidence in the U.S. decreased by nearly 1 percent per year between 2003 and 2007, with mortality falling by twice that figure across all four years, thanks largely to advances in diagnostic imaging, showed the findings of a report published in the April edition of the Journal of the National Cancer Institute.
Outpatient intra-arterial yttrium-90 (Y-90) radioembolization provides an anti-tumoral effect in liver cancer patients where chemotherapy failed, according to a multi-institutional study presented at the Society of Interventional Radiology's 36th annual scientific meeting in Chicago. The study examined the impact of treating liver tumors with higher doses of Y-90 than previously tried.
A large proportion of physicians do not participate in clinical cancer trials, with a lack of funding and underdeveloped hospital infrastructures and IT preventing nearly half of cancer specialists from enrolling patients in research trials, according to a study published Feb. 11 in the Journal of the National Cancer Institute.
|
|
|
|
RSS 
